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Tissue barriers involving epithelial and endothelial cell layers are critical to homeostasis, regulating passage of water, macromolecules, cells
and certain classes of small molecules via two distinct cellular mechanisms, transcellular or paracellular. Endothelial or epithelial barrier
dysfunction is a key component of pathophysiology in diverse diseases and injuries that have a broad impact on survival and quality of life.
However, effective and safe small molecule therapeutics for these disorders are lacking. Success in development would therefore fill a major
unmet medical need across multiple disease areas. Myosin light chain kinase (MLCK), a highly specialized calcium/calmodulin (CaM) regulated
protein kinase, modulates barrier function through its regulation of intracellular contractile processes. MLCK levels and activity are increased in
various animal models of disease and in human clinical disease samples. Our prior work with a genetic knockout (KO) mouse strain for the long
form of MLCK, MLCK210, has identified MLCK as a drug discovery target for endothelial and epithelial barrier dysfunction. We describe here
the development of a selective, bioavailable, stable inhibitor of MLCK that attenuates barrier dysfunction in mice comparable to that seen with the
MLCK KO mice. The inhibitor compound 6 is stable in human microsomal metabolic stability assays and can be synthesized in a high-yielding
and facile synthetic process. These results provide a foundation for and demonstrate the feasibility of future medicinal chemistry refinement
studies directed toward the development of novel therapies for disorders involving barrier dysfunction.
© 2006 Elsevier B.V. All rights reserved.Keywords: Myosin light chain kinase; Barrier dysfunction; Genetic knockout; Inflammatory disorder; Drug discovery; Structure–activity relationship1. Introduction
Cellular layers that form barriers between tissues are a
defining feature of evolutionarily advanced organisms, and pro-
vide a key point of regulation in such complex organisms.
Tissue barriers involving epithelial and endothelial cell layers
are critical to homeostasis, and a source of major dysfunction
in diverse debilitating and life-threatening diseases [1–4].
Endothelial and epithelial cell layers can form tissue barriers,
thereby regulating passage of water, macromolecules, cells and
certain classes of small molecules via two distinct cellular me-
chanisms—transcellular (passage through the cell) or paracel-
lular (passage via gaps between adjacent cells) [5,6]. Various
stresses can result in barrier dysfunction, leading to leakage of
proteins and excessive fluids into tissue, which can eventually
lead to disease or organ failures if not resolved by intervention⁎ Corresponding author.
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doi:10.1016/j.bbamcr.2006.08.007[7–11]. Such barrier dysfunctions are the result of an imbalance
between intercellular adhesive forces, such as adherence
junctions, and intracellular contractile forces that are linked to
these adherence structures and that tend to pull cells apart, such
as actomyosin regulatory complexes and the contraction cycle of
the intracellular myosin II complex [5,12–14].
Activation of the myosin II complex requires phosphoryla-
tion of themyosin regulatory light chains (MLC) bymyosin light
chain kinase (MLCK), a highly specialized calcium/CaM
regulated protein kinase that has MLC as its only physiological
substrate [15]. The predominant isoform ofMLCK present in the
endothelial and epithelial cells involved in tissue barrier regula-
tion is the long form, or MLCK210 [15–17]. The most direct
demonstration of the in vivo importance of MLCK210 in tissue
barrier function and dysfunction comes from the analysis of
mice in which the gene for MLCK210 has been knocked out
[18]. MLCK210 knockout (KO) mice are protected from
inflammation linked injury and death [18,19]. For example,
the KO mice are protected in an animal model of acute immune-
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microbial toxin induced injury similar to that seen in sepsis [18].
The former injury model involves epithelial barrier functions
and the latter involves endothelial barrier functions. Congruent
with the MLCK210 KOmouse results, wild type mice subjected
to the same injuries are protected by treatment with selective
MLCK inhibitors [18,19]. In addition to providing a well
established link betweenMLCK and tissue barrier functions that
are points of susceptibility in disease progression in inflamma-
tion related injuries, these recent studies with MLCK210 KO
mice and therapeutic doses of MLCK inhibitors established
MLCK as a potential non-immune therapeutic target for certain
inflammation related disorders.
A non-immune mechanism of intervention is a complement
to therapies already in use to treat inflammation disorders in the
clinic. Currently, therapeutic approaches in diseases such as
inflammatory bowel disorders or complications of severe bac-
terial infection are focused on the cytokines which are up-regu-
lated and are among the active mediators of both endothelial and
epithelial barrier dysfunction [7,20,21]. Antibody therapies
targeting these cytokines have been used, but they have limited
stability, restricted utility due to their limited tissue distribution,
and are expensive protein therapeutics with individual sets of
safety problems [22]. Non-protein therapies involving small
molecules such as statins and glucocorticoids have some clinical
effectiveness for inflammatory conditions, but are limited by
their multiple biological effects and toxicity [13,23,24]. Thus,
there is an unmet need for new and safe compounds to use as a
co-therapy with other drugs or mechanical devices to attenuate
barrier dysfunctions.
Based on the demonstrated protection from epithelial and
endothelial barrier dysfunction afforded by inhibition of
MLCK by gene knockout or use of kinase inhibitors, small
molecule inhibitors of MLCK are potential lead compounds
for the above unmet medical need. However, currently
available inhibitors are peptidic in nature [19,25–27] or are
expensive bioavailable small molecules for chemical biology
research that are not readily amenable to further development
[18]. We report here initial attempts to address this unmet
medical need by development of a lead compound that is a
MLCK inhibitor with more attractive cost-of-goods and
molecular properties consistent with the potential use of this
compound as a therapeutic. We show that this lead compound
has appropriate in vivo function by attenuating endotoxin
induced pulmonary vascular leak in mice. Further, in vitro
screens for potential metabolic stability using human liver
microsomes indicate its attractiveness for use in future human
studies.2. Materials and methods
2.1. Chemistry
2.1.1. General
Chemicals were purchased from Aldrich (Milwaukee, WI) or VWR
International, and used as received. All solvents were used as received unless
stated otherwise. All water used was Milli-Q water obtained using a Biocel A10water purification system from Millipore Corporation (Bedford, MA). Micro-
wave irradiation was carried out using the CEM Discover microwave synthesis
system (Matthews, NC).
Progression of synthetic reactions was monitored by analytical HPLC on a
Rainin Instruments HPLC using a Supelco C18 reverse phase column
(250×4.6 mm, 5 μm) at a flow rate of 1.0 ml/min and monitored by UV
absorption at 260 nm. The mobile phase consisted of 0.1% (v/v) formic acid
(Fluka) in water as reagent A and 80% acetonitrile/0.08% formic acid/water as
reagent B.
2.1.2. Synthesis
All compounds were synthesized using a variation of a previously described
synthetic scheme [28,29]. Details of synthesis for each compound made as part
of this study are summarized under Results.
2.1.3. Analytical chemistry
Purity of compounds and bioanalytical analyses were determined on a
Dionex HPLC system (Dionex, Sunnyvale, CA) using a Phenomenex (Torrance,
CA) Luna C18 column (250×2.0 mm; 5 μm) and guard column with a flow rate
of 0.2 ml/min. The system consisted of a Dionex P680 pump, ASI-100 auto-
sampler, andUVD170U ultraviolet detector. Reagents A and Bwere as described
above, unless otherwise stated. For determination of compound purity, the
gradient consisted of a linear change from 0 to 100% of reagent B over 30 min.
UV absorption was monitored at four wavelengths (215, 230, 260 and 300 nm)
with the 260 nm trace being reported. The approximate upper and lower limits of
detection for the 3-amino-6-arylpyridazine analogs are, respectively, 2 μg and
0.03 μg. For purity analysis by HPLC, 0.5 μg of each compound was analyzed.
All compounds were characterized minimally by electrospray mass spectro-
scopy (ESI) and HPLC. Compounds used for metabolic stability and in vivo
studies were additionally characterized by high resolution mass spectra (HRMS)
and 1H-NMR. NMR spectra were acquired on a Varian Inova 500 MHz spectro-
meter at room temperature. ESI mass spectra were collected on a Micromass
Quattro II Triple Quadrupole HPLC/MS/MSMass Spectrometer. HRMS spectra
were obtained on a VG70-250SE mass spectrometer. Melting point data for
compound 6 (118–120 °C) were acquired on a Büchi Melting Point B-540
(Flawil, Switzerland).
2.2. Screening for in vitro inhibition activity
MLCK inhibitory activity screens [25] were done by incubation with 20 μM
peptide substrate (KKRPQRATSNVFAM-NH2), 200 μM ATP and [
32P]-ATP
(2.5 μCi per reaction) in assay buffer (50 mM HEPES, pH 7.5 with KOH, 5 mM
MgCl2, 0.15 M KCl, 0.015 M NaCl, 1 mM DTT) with 0.1 mM CaCl2 and 1 μM
calmodulin (New England Biolabs, MA). Reactions were initiated by addition of
MLCK protein and incubated for 20 min at 25 °C. Reactions were spotted onto
P-81 paper (Whatman, Clifton, NJ), washed with 75 mM H3PO4 and 95%
EtOH, and quantified by scintillation counting in EcoScintO (National
Diagnostics, Atlanta, GA). Testing of compounds for kinase inhibitory activity
against the structurally and functionally related kinase death-associated protein
kinase (DAPK) and the signal transduction pathway relevant kinases protein
kinase A (PKA) and protein kinase C (PKC) were performed as described
[28,30–33] by using the corresponding peptide substrates and assay conditions.
2.3. Screening for in vivo function
2.3.1. Animals
Adult (20–30 g) female C57Bl/6 mice were obtained from a commercial
vendor (Harlan, Indianapolis, IN). The generation and characterization of the
MLCK210 KO mouse strain was previously described [18]. All animal
procedures were performed in accordance with relevant National Institutes of
Health guidelines and approved by the Institutional Animal Care and Use
Committee of Northwestern University.
2.3.2. Measurement of bacterial toxin-induced pulmonary vascular leak
Pulmonary vascular leak after injurious endotoxin exposure was examined
essentially as previously described [18] except using the increase in Evans blue
dye in the lung as a quantitative end point [34]. Treatments with lipopolysac-
charide (LPS, from S. typhimurium, Sigma, St. Louis,MO), Evans blue dye (Alfa
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administration. Mice were administered either an injurious concentration
(10 mg/kg) of LPS or saline as part of the control group. A subset of mice (drug
treated) was administered MLCK inhibitor (5 mg/kg). Animals were euthanized
with 200 mg/kg of pentobarbital 24 h after treatments, and blood was drawn by
intracardiac puncture into Microtainer tubes (SST®, BD Biosciences, Bedford,
MA) and centrifuged at 6000×g for 5 min for serum preparation. For
measurement of Evans blue dye levels, mice were perfused through the right
ventricle with a phosphate buffer solution, lungs were harvested and weighed,
and the Evans blue was extracted by incubation with 100% formamide (Sigma,
St. Louis, MO) at 50 °C for 18–24 h. The levels of Evans blue in the serum and
the tissue supernatant were then determined by measuring the absorbance at
620 nm. The reading at 620 nm (E620) was corrected for the presence of
contaminating heme pigments in the samples by measuring the absorbance at
740 nm (E740) and using the correction formula E620=E620− (1.426×E740+
0.030). The amount of Evans blue in the samples was then calculated using a
standard curve obtained with known amounts of Evans blue. The results were
normalized by considering themean level of Evans bluemeasured in LPS-treated
mice as 100%.
2.4. In vitro screening for metabolic stability with human liver
microsomes
A standard screening of compounds for in vitro metabolic stability with
human liver microsomes [35] was done at 5 μM of compound using
commercially available, calibrated human liver microsomes and a NADPH-
regenerating system (BD Biosciences, Bedford, MA). Briefly, reaction mixtures
were prepared in 0.1 M potassium phosphate buffer and contained 1.6 mg/ml
microsomal protein, 5 μM test compound, 1.3 mM NADPH, 3.3 mM MgCl2,
0.4 U/ml glucose-6-phosphate dehydrogenase, and 3.3 mM glucose-6-phosphate
in a total volume of 300 μl. Reactions were incubated for 10 and 30 min at 37 °C
and halted by addition of cold acetonitrile. The mixture was centrifuged at
10,000×g for 10min and 20 μl of supernatant was analyzed byHPLC to quantify
the percentage of the initial amount of compound remaining after incubation. The
HPLC mobile phase consisted of 5% acetonitrile in water as reagent A and 80%
acetonitrile/0.08% formic acid/water as reagent B at a flow rate of 0.2 ml/min.
The gradient consisted of the following variations in %B: begin with %B at 0 for
2 min, 0–100% from 2 to 22 min, isocratic until 24 min. Peak quantification was
done based upon absorption measurements at 260 nm relative to a standard curve
obtained by serial dilutions of known amounts of compounds.
3. Results
3.1. Small-molecule inhibitor design and synthetic strategy
The use of a dual headed scaffold with a 6-phenyl-3-amino-
pyridazine group at one end and a variable amine at the other end
was selected as a starting point for lead compound development
due to its synthetic accessibility and prior precedent to serve as a
scaffold for kinase inhibitors [28,29,36,37]. Compounds 1 and 2
(Table 1) have been described previously [18,29]. Compound 1
is the selective MLCK inhibitor used to validate the results with
the MLCK210 KO mice [18]. Compound 2 [29] is a non-
selective MLCK inhibitor with an IC50 value of 2.71 μM that
also inhibits the structurally-related, calmodulin regulated
DAPK and the physiological pathway relevant PKC. As a goal
for compound selectivity in the current study, we set an initial cut
off value of 10-fold lower IC50 for MLCK compared to DAPK,
PKC and PKA.
As a starting point in synthetic planning, we retained the
6-phenyl-3-amino pyridazine portion of compound 2 and varied
the other lobe of the dual headed molecule [36], based on the
precedent of varying kinase inhibitor affinity and selectivity bydiversification of the amine used in the terminal amination step
in the synthetic scheme. Molecular modeling suggests [31] that
the ability to modulate kinase selectivity with variation of the
amine might be due to that portion of the molecule binding
within the peptide substrate recognition region of the kinase.
Consistent with this model, the starting scaffold, the blocked
compound 3 and the reactive precursor compound 4 (see Fig. 1),
lack an amide bond extending this portion of the molecule and
do not have kinase inhibitor activity under the conditions used
(data not shown). In contrast, compounds 5–10 have amines
coupled to the acid at this position of compound 4, and exhibit
kinase inhibitory activity of varying affinity and selectivity
(Table 1).
The amines chosen to couple to the alkylated 6-phenyl pyri-
dazine scaffold, compound 4, were required to fit the criteria for
production of an inhibitor with low cost-of-goods and ease of
synthesis if it was found to be active in kinase inhibition screens.
Specifically, the criteria for choice of amines for in-parallel
syntheses of candidate inhibitors were that the amines should be
primary, aliphatic amines to increase the potential for high
yielding, facile coupling reactions. Precedence in the literature
for kinase inhibition [38–41] was used to prioritize which
amines to test first, as was commercial availability. A computed
solubility (log S) filter was also put in place to first synthesize
compounds with computed aqueous solubility of log S≥−3
based on the need for more soluble compounds for use as
injectables, as the anticipated clinical administration would be
injection or in intravenous fluids.
Implementation of these filters led to the choice of two
amines – histamine and 2-(1-methylpyrrolidin-2-yl) ethana-
mine – that resulted in the synthesis of the first potential kinase
inhibitors compounds 5 and 6. Based on activity results with
these two compounds (Table 1), additional analogs (compounds
7–10) were made in order to gain initial insight into how the
structure of these inhibitors was related to kinase inhibitory
activity.
3.2. Synthetic scheme and characterization of title compounds.
The synthetic scheme for the title compound 6 is given in Fig.
1. Variations of this scheme were used for the synthesis of the
various compounds whose kinase inhibitory activities (Table 1)
and in vivo functions were characterized as part of the studies
summarized in this report. Specific details and experimental
narratives for each intermediate compound and final inhibitor
compound are summarized in a following section. All
compounds were screened for purity and evidence of correct
product formation by HPLC and mass analysis as described in
Materials and methods. These results are summarized in Table 2.
Those compounds with improved kinase inhibitory activity
(compounds 5, 6 and 10) were characterized further to validate
structure by HRMS and 1H-NMR analysis. The characteriza-
tions validated the proposed structures of these three novel
compounds, as summarized below.
Compound 5, N-(2-(1H-imidazol-4-yl)ethyl)-11-(6-imino-
3-phenylpyridazin-1(6H)-yl)undecanamide, gave the following
results consistent with its proposed structure: 1H-NMR (DMSO-
Table 1
In vitro inhibition of kinases
nd=not determined.
* Advanced Chemistry Development(ACD)/Solubility database 9.03. log S is computed intrinsic solubility of the compounds at pH 7.4.
** Previously reported [18,29].
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(d,J=3.5Hz,1H),7.75 (dd,J=9.5Hz,J=3.5Hz,1H),7.59 (s, 3H),
7.56(d, J=3.5Hz,1H),4.35 (s, 2H),3.37 (s, 7H),3.25 (s, 3H),2.61
(d, J=3.5 Hz, 2H), 2.03 (d, J=4 Hz, 2H), 1.85 (s, 2H), 1.46
(s, 3H), 1.36 (s, 5H), 1.25 (s, 9H); HRMS (C26H36N6O) ex-
pected 448.2945, found 448.2937.
Compound 6, 11-(6-imino-3-phenylpyridazin-1(6H)-yl)-N-(2-
(1-methylpyrrolidin-2-yl)ethyl)-undecanamide, gave the following
results consistent with its proposed structure: 1H-NMR (DMSO-
d6), δ 8.35 (m, 2H), 7.99 (m, 2H), 7.80 (d, J=5.0 Hz, 1H), 7.71
(d, J=9.0 Hz, 1H), 7.58 (d, J=4.5 Hz, 2H), 4.31 (t, J=6.5 Hz,
2 H), 3.05 (quintet, J=7 Hz, 2H), 2.99 (m, 1H), 2.55 (s, 3H), 2.23
(s, 2H), 2.12 (m, 2H), 2.02 (t, J=7.0 Hz, 2H), 1.92 (m, 1H), 1.87
(m, 2H), 1.74 (m, 1H), 1.63 (m, 2H), 1.46 (m, 2H), 1.37 (m, 4H),
1.25 (s, 8H); HRMS (C28H43N5O) expected 465.3462, found
465.3454.Compound 10, N-(2-cyclopentylethyl)-11-(6-imino-3-phe-
nylpyridazin-1(6H)-yl)undecanamide, gave the following
results consistent with its proposed structure: 1H-NMR
(CDCl3), δ 8.00 (d, J=9.5 Hz, 1H), 7.83 (m, 2H), 7.78 (dd,
J=9.0 Hz, J=2.5 Hz, 1H), 7.51 (bs, 3H), 5.90 (s, 1H), 4.37
(t, J=6.5 Hz, 2H), 3.20 (quartet, J=6.0 Hz, 2H), 2.13 (t,
J=7.5 Hz, 2H), 1.91 (m, 2H), 1.74 (s, 2H), 1.57 (m, 4H), 1.48 (d,
J=6 Hz, 4H), 1.40 (m, 3H), 1.34 (m, 2H), 1.25 (s, 10H),
1.07 (s, 2H); HRMS (C28H42N4O) expected 450.3353, found
450.3346.
3.3. Detailed synthetic narrative
The starting scaffold (compound 4) that was used to generate
inhibitors by reaction with the various coupled amines was
synthesized as described previously [29]. Briefly, 11-bromo
Fig. 1. Synthetic scheme for production of compound 6. (i) EtOH, HCl, rt, 48 h;
(ii) DMF, 3-amino-6-phenyl pyridazine, 80 °C, 12 h; (iii) AcOH,HCl, reflux, 5 h;
(iv) HBTU/HOAT, DIEA, 2-(1-methylpyrrolidin-2-yl)ethanamine, NMP, micro-
wave irradiation, 200 W, 15 min, 55 °C; then 300 W, 20 min, 60 °C.
Table 2
Analytical chemistry for compounds 1–10
Compound ESI HPLC tr(min)/purity
1 470.1 (MH+) 10.8/98%
2 509.3 (MH+) 22.0/90%
3 384.4 (MH+) 21.0/97%
4 356.3 (MH+) 19.0/95%
5 225.3 (MH+2/2), 449.3 (MH+) 16.5/95%
6 233.8 (MH+2/2) 14.3/98%
7 424.3 (MH+) 15.0/95%
8 241.0 (MH+2/2) 14.2/90%
9 227.2 (MH+2/2) 14.4/98%
10 451.7 (MH+) 20.2/95%
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ethanol with 4N HCl in dioxanes (10 mL, 0.25 mL/mmol acid)
and stirred for 48 h at room temperature. The ethanol was
removed under reduced pressure leaving the product as a yellow
oil. The oil was used without further purification in the next step.
Ethyl 11-bromo undecanoate (8 g, 27.3 mmol) was dissolved in
30 mL DMF and heated to 80 °C. Subsequently, 0.77 equiv of
3-amino-6-phenyl pyridazine (3.6 g, 21 mmol) was dissolved in
minimal DMF and added dropwise to the solution. The reaction
was capped and stirred for 8 h. After the reaction was cooled to
ambient temperature and diluted with water, the mixture was
poured slowly onto ether (100 mL) giving a white solid. The
solid was filtered and rinsed with hexanes to afford the product,
compound 3, in 86% yield. To deprotect the ethyl ester,
compound 3 (6.8 g, 17.8 mmol) was then dissolved in 90 mL
glacial acetic acid and 18 mL of 12 N HCl and refluxed for 5 h.
The solvent was removed under reduced pressure, and the
resulting residue triturated with ether to form a pink solid. The
solid was dissolved in ethyl acetate and precipitated out with
hexanes to give the product, compound 4, as a white solid in
95.2% yield. The same procedure was followed starting with
8-bromooctanoic acid instead of 11-bromoundecanoic acid [29]
for the synthesis of compound 7. The protection of the acid
proceeded with 69% yield and was used without further
purification in the alkylation step. The alkylation step was
performed in 71% yield followed by deprotection of the ethyl
ester in 97% yield.
For the synthesis of compound 8, 3-chloro-6-phenyl pyridazine
(0.5 g, 2.6mmol)was aminated at the 3-position in a reaction vessel
with 5 equiv methylamine HCl (877 mg, 13 mmol) and 5 equiv
triethylamine (1.5 mL, 13 mmol). The reactants were dissolved in
15 mL butanol and purged with argon. The vessel was capped and
placed at 130 °C for 24 h. Upon cooling to ambient temperature,
white crystalline needles formed and were filtered off. Water was
then added to the filtrate, forming a white solid precipitate, which
was filtered to give the product in 83% yield. This compound was
then alkylated with ethyl 11-bromoundecanoate and deprotected as
described above with comparable yields.For the amination reactions, both conventional and micro-
wave-assisted coupling reactions were explored. The conven-
tional coupling proceeded in moderate yields, using standard
amination coupling conditions. Briefly, compound 4 was placed
in a capped vessel and dissolved in dry 1-methyl-2-pyrrolidi-
none (NMP). 1.1 equiv of 1-hydroxy-7-azabenzotriazole (HOAT)
and 4 equiv of diisopropyl ethyl amine (DIEA) were added. The
vessel was purged with argon, capped, and cooled to 0 °C. 1.1
equiv 1-ethyl-3-(3-dimethylamino propyl) carbodiimide hydro-
chloride (EDC) was then added, and the vessel purged again
with argon. The mixture was stirred at 0 °C for 45 min, and 1.5
equiv of the amine was added. The reaction mixture was purged
with argon, removed from the ice bath and allowed to stir at
room temperature until complete. This method was applied for
compounds 5 through 8.
For compound 5, the reaction was complete after 48 h, and
water (10 mL) was added to the solution, forming a suspension.
The suspension was filtered to give a white solid in 47.8% yield.
Compound 6 was also complete after 48 h, and the red orange
solution was diluted with water (10 mL) to give a cloudy orange
suspension. The aqueous phase was washed with ether
(2×5 mL) and extracted with chloroform (3×15 mL). The
chloroform layers were combined, dried over magnesium sulfate
and evaporated under reduced pressure. The residue was then
dissolved in ethyl acetate and washed with water (3×30mL) and
sodium bicarbonate (2×30 mL) to remove residual amine. The
ethyl acetate was dried and evaporated under reduced pressure to
give a red-orange oil. The oil was purified with solid phase
extraction (SPE) using equilibrated C18 Sep-Pak® cartridges
(Waters, MA), and eluted with 25% acetonitrile in 0.1% formic
acid to give a pale orange solid in 46% yield.
Compound 7 was also a red-orange mixture, but did not form
a suspension upon the addition of water. The aqueous mixture
was washed with ethyl acetate (3×20 mL) and chloroform
(3×30 mL), and then evaporated under reduced pressure,
producing a white solid in 30% yield.
Amination of compound 8 was complete in 24 h, and water
was added to the reaction mixture to form a suspension. The
mixture was extracted with chloroform (3×25 mL), and the
organic layers were combined and subsequently washed with
sodium bicarbonate (5×50 mL) to remove unreacted acid
starting material. The organic layer was dried with magnesium
sulfate and evaporated under reduced pressure. The solid was
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formic acid to afford the product 8 in 41% yield.
Due to the low yields seen for conventional coupling,
microwave-assisted coupling was also investigated. Following
the procedure of Santagada et al. [42], compound 4 was placed
into a 10 mL microwave reaction vessel with 1.1 equiv 2-(1H-
benzotriazole-1-yl)-1,1,3,3,-tetramethyluronium hexafluoro-
phosphate (HBTU), 1.1 equiv HOAT, 2 equiv DIEA and 1
equiv amine. The reagents were dissolved in 3 mL NMP and
purged with argon. The vessel was sealed and placed in the
microwave first for 15 min at 55 °C (200W) and then for 20 min
at 60 °C (300 W).
Compound 6 was synthesized by this method to compare the
microwave and conventional syntheses directly. After 35 min of
reaction time, the mixture was poured over sodium bicarbonate
(10 mL) and extracted with ethyl acetate (5×20 mL). The ethyl
acetate layers were combined, dried with magnesium sulfate,
and evaporated under reduced pressure. The remaining red
orange oil was purified with SPE and eluted with 25%
acetonitrile in 0.1% formic acid to afford a pale orange solid
in 90% yield. Compared to the conventional synthesis, the yield
doubled under the microwave-assisted synthesis conditions.
Based on the initial microwave-assisted results, analogs 9 and
10 were also synthesized using microwave heating. For
compound 9, the Boc-protected pyrrolidine was coupled onto
the compound 4. When the reaction was complete, the yellow
solution was poured onto sodium chloride (20 mL) and extracted
with ethyl acetate (3×20 mL). The organics were collected,
dried over magnesium sulfate, and evaporated under reduced
pressure to afford the product as brown oil in 96.4% yield. The
product was confirmed by ESI and used without further puri-
fication in the deprotection step. The oil (300 mg, 0.54 mmol)
was dissolved in a solution of 3MHCl in ethyl acetate and stirred
at room temperature [43]. After 30 min no starting material
remained, and the reaction mixture was evaporated under re-
duced pressure to afford the product as yellow oil. The com-
poundwas then purified by SPE and eluted with 25% acetonitrile
in 0.1% formic acid in 86% yield.
The synthesis of compound 10 followed the same overall
microwave procedure. At the end of the reaction, the orange
mixture was poured over saturated sodium chloride (20 mL) and
extracted with ethyl acetate (3×20 mL). The organic layers were
combined and washed with water (5×30 mL) and sodium
bicarbonate (3×30 mL). The organic layers were combined and
dried with magnesium sulfate and evaporated under reduced
pressure to provide the compound as a pale brown solid. The
compound was purified with SPE and eluted with 50%
acetonitrile in 0.1% formic acid in 79% yield.
3.4. Screening for in vitro inhibitory activity
Final compounds were initially screened for concentration
dependent inhibition of MLCK (Table 1). Compound 5 inhibits
MLCKwith an IC50 value of 6.33 μM and is more selective than
compounds 1 or 2. Compound 6 inhibits MLCK with a com-
parable IC50 of 13.3 μM and is also highly selective for MLCK.
In the case of protein kinase inhibitors, values for IC50 thatapproximate or are better than the value for the ATP or peptide
substrate Km values make such selective compounds candidates
for further in vivo testing of function.
Previously [28,29,36], aliphatic amines such as that found in
compound 6 had not been examined. We were therefore inte-
rested in examining the features of compound 6 to gain insight
into the structural requirements of this novel compound for
MLCK activity. In an attempt to enhance solubility and decrease
the number of rotatable bonds in the molecule, compound 7 was
synthesized with an alkyl chain that is 8 carbons long, versus the
11 carbons in compound 6 (Table 1). However, it was observed
that shortening the carbon chain diminished the inhibitor activity
of the compound for MLCK. This was also observed for an 8
carbon analog of compound 5 (data not shown). The next varia-
tion was designed to simplify the electronics of the pyridazine
core, and potentially confer greater stability of the compound.
This was done by methylating the free amino group on the
pyridazine ring in compound 8. However, when tested in vitro,
compound 8 did not have any inhibitory activity against MLCK
(Table 1).
The observation that changing the amine on the pyridazine
ring from a primary to secondary amine drastically reduced
the activity of the inhibitor for MLCK prompted investigation
into the tertiary nitrogen present in 2-(1-methylpyrrolidin-
2-yl). To investigate this, compound 9 was designed without
the methyl group. A small drop in activity was observed, im-
plying that this amine is less crucial to the compound's
activity than the exocyclic amine of the pyridazine ring. To
further explore the role of the nitrogen in the pyrrolidine ring,
compound 10 was designed with no nitrogen present. Com-
pound 10 was found to be selective for MLCK (2.52 μM) and
more active in vitro than the parent compound 6 in MLCK
inhibition (Table 1). Although the activity of compound 10 was
interesting and may warrant further study, its computed
molecular properties (Table 1) do not fit the prioritization
criteria outlined above. Compound 6 appears, therefore, to be the
best overall inhibitor in terms of in vitro activity, selectivity and
molecular properties and was given priority for in vivo screening
of function.
3.5. In vivo screening for function
With the hypothesis that an MLCK inhibitor can inhibit
pulmonary vascular leak resulting from increased endothelial
permeability, we tested compound 6 in vivo for protection from
LPS induced vascular leak in the lungs. We assessed the
pulmonary vascular leak by measuring the extravasation of
Evans blue dye into the lung tissue after an injurious exposure to
LPS [18]. The injection of LPS in the mice induced a significant
increase in the Evans blue level in the lung tissue, indicating an
increase in vascular leak in this tissue (Fig. 2). The results
screen showed that compound 6 was efficacious in vivo to
reduce LPS-induced pulmonary vascular leak, comparable to
the level measured in the lungs of saline-treated control mice
(Fig. 2A). This level of suppression is comparable to that seen
with MLCK 210 KO mice. This control experiment is shown in
Fig. 2B.
Fig. 3. Compound 6 exhibits in vitro metabolic stability in screens with human
liver microsomes. The amount of compound 6 and its carbocycle analog
compound 10 remaining after 10 and 30 min incubations with commercially
available human liver microsomes was determined by HPLC analysis. The
majority of compound 6 (filled bar) remains after 10 and 30min incubation times,
in contrast to the carbocycle compound 10 (open bar). The levels of compound 10
are significantly different (***p<0.001) at 10 and 30 min compared to zero min.
Data shown represent the mean±SEM of triplicate samples at each time point.
Results are analyzed by one way-ANOVA followed by a Neuman–Keuls post-
hoc test.
Fig. 2. Compound 6 protects mice from bacterial toxin-induced pulmonary
vascular leak. (A) TherapywithMLCK inhibitor compound 6 protects mice from
pulmonary vascular leak as determined by decreased levels of Evans blue dye
appearing in the lungs. Mice were administered Evans blue dye and exposed to
bacterial toxin lipopolysaccharide (LPS) or saline (Sal) by intraperitoneal (i.p.)
injection. A subset of themice exposed to LPSwere also injected i.p. withMLCK
inhibitor compound 6. The relative levels of dye appearing in lung tissue 24 h
later were then determined for all mice. Mice exposed to LPS (10 mg/kg) and
receiving 5 mg/kg of the compound 6 (LPS+cmpd6) exhibit lung levels of dye
comparable to that seen with control mice not exposed to LPS and administered
only saline (Sal). The protection afforded mice by compound 6 therapy is
reflected in the significantly lower (*p<0.05) levels of dye in the lungs of these
mice compared to those not receiving therapy (LPS). (B) The protection afforded
by therapy with compound 6 (panel A) is comparable to the protection seen by
genetic knockout (KO) of the target MLCK. In a parallel control experiment,
micewere administered Evans blue dye, exposed to LPS or saline, and lung tissue
examined 24 h later, as in panel A. MLCK210 KOmice are protected from LPS-
induced vascular leak (KO+LPS) to levels comparable to saline treated control
wild type mice (Sal). The protection afforded mice by genetic KO of the target
MLCK is reflected in the significantly lower (***p<0.001) levels of dye in the
lungs of these mice compared to those not receiving therapy (LPS). Data shown
represent the mean±SEM for 4–5 mice in each group. Results were analyzed by
one way-ANOVA followed by a Neuman–Keuls post-hoc test.
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In order to extend the potential utility of compound 6 in future
human studies and justify further refinement of compound 6, we
subjected this novel compound to a standard human liver
microsomes (HLM) metabolic stability screening assay [35].
Fig. 3 shows that compound 6 is stable in the HLM assay, as the
levels of compound 6 measured in the HLM mixture did not
decrease during incubation. As a comparative control, com-
pound 10 was tested for stability in the HLM assay. As shown,
the amount remaining at 10 and 30 min is significantly lower
than compound 6. Efficacy and metabolic stability are
independent but related events and one cannot extend HLM
metabolic stability results to the prediction of in vivo stability in
humans, but the results further indicate the development promise
of compound 6.
4. Discussion
The successful development of the lead compound 6
targeting MLCK demonstrates the feasibility for pursuit of a
new class of therapeutics that address a major unmet medical
need across multiple areas of disease and injury. The precedent
described here for this bioavailable MLCK inhibitor also de-
monstrates that the development of integrative chemical biologyreagents for in vivo dissection of protein kinase mediated,
calcium signal transduction pathways is a realistic goal.
The lead compound 6 is selective for MLCK compared to
closely related protein kinases. For example, it is over 76 times
more selective for MLCK versus DAPK, another calcium/CaM
regulated protein that has a catalytic domain structurally similar
to that of MLCK [32], similar peptide substrate preferences
[32], and the novel ability to mimic MLCK's unique ability to
phosphorylate myosin light chains at Ser19 [30,44]. The
compound is also selective for MLCK over other protein kina-
ses, such as PKC and PKA, that are involved in potentially
convergent signaling pathways or in vivo cross-talk with
MLCK regulated processes. The selectivity of the inhibitor was
accomplished by diversification of an N2-alkylated aminopy-
ridazine scaffold via facile amination reactions. It was observed
that various aliphatic amines containing a terminal 5-membered
ring structure could be incorporated into the inhibitor's structure
(compounds 6, 9, 10) without a major loss of MLCK inhibitory
activity. However, the placement of the amines in relation to the
scaffold appears to be critical, as shortening the carbon linker by
3 atoms destroys inhibitory activity (compound 7). These
results are consistent with previous molecular modeling studies
[31] that suggested the amine portion of these bi-headed
molecules interacts with regions of protein kinase catalytic
domains involved in peptide substrate binding. The lead com-
pound 6 shows mixed kinetics, suggesting that it interacts with
both the ATP and peptide binding domains of the kinase (data
not shown). This implies that future compound refinement
might allow selective targeting of inhibitor interactions to the
peptide substrate binding region of MLCK, and that similar
approaches may be viable for other signal transducing protein
kinases.
The lead compound 6 is stable in HLM screens for potential
human first pass metabolic susceptibility, a common cause of in
vivo efficacy failure or complications in human therapeutic
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forms that are involved in the metabolism of the majority of
currently used drugs are a major component of the metabolic
activity in these calibrated HLMs. This includes P450 isoform
CYP2D6, the major source of functional polymorphisms in
human first pass metabolism of drugs. The fact that compound 6
is stable in these HLM assays is promising as it suggests that
there will be less individual variance in metabolism of com-
pound 6 or future analogs, and less potential for drug–drug
interactions. The results also raise the possibility for enhancing
therapeutic efficacy in future drug development by refining
either pharmacokinetics or pharmacodynamics of such com-
pounds. The synthesis of the lead compound 6 proceeds with
good synthetic yields and is attractive from a potential produc-
tion perspective, starting with commercially available and
inexpensive starting materials. Therefore, the biological results,
synthetic scheme, and the computed molecular properties [45]
make the lead compound 6 compatible with future development
and formulation as a therapeutic for major unmet medical needs
involving tissue barrier dysfunction, especially in critical care
medicine or intestinal disorders, clinical areas that are lacking
robust and safe small molecule therapies.
Endothelial and epithelial barrier dysfunctions are key ele-
ments in the pathophysiology of diverse diseases in which
targeting MLCK is a viable approach based on the accumulating
body of evidence using bioavailable inhibitors in animal models
of disease or MLCK210 KO mice in models of disease relevant
injuries [18,19]. Consistent with our previous results [18], we
have shown here that MLCK can be a potential target for treat-
ment of pathologies that involve endothelial barrier dysfunction
as an underlying cause. The human disease counterparts are
diverse, including sepsis associated organ failure, pulmonary
hypertension related tissue injury, and complications of severe
burn. For example, thermal injury induces massive tissue edema
in patients [11]. MLCK dependent pathways have been impli-
cated in this pathophysiology progression and inhibition of
MLCK decreased the leak induced by the thermal injury [46,47].
MLCK inhibitors also have a potential role in treatment of
epithelial barrier dysfunction related disorders, such as inflam-
matory bowel disease. MLCK is involved in the regulation of
tight junctions in response to various pathological stimuli [5],
and MLCK expression and enzymatic activity are increased in
colon biopsies from patients with inflammatory bowel disease
[48]. Further, treatment with MLCK inhibitors in animal models
or deletion of MLCK210 restores intestinal barrier function in
response to diverse pathological stimuli [19,27,49]. This
accumulating body of disease-relevant evidence indicates that
the lead compound 6 is a promising starting point for future
medicinal chemistry refinement investigations that have the
potential to develop new classes of drugs for the prevention or
treatment of diseases and injuries associated with tissue barrier
dysfunctions.
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